METTL3 and familial pancreatic carcinoma: In pancreatic cancer, absence of METTL3 resulted in increased sensitivity to anticancer treatment, in particular to chemotherapy with gemcitabine, 5-fluoruracil, and platinum (Taketo et al. 2018).